Comparative Effects of Ca Slow Channel Blockers on the Hamster Hereditary Cardiomyopathy

  • G. Jasmin
  • L. Proschek
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 39)


The use of Ca slow channel blockers for the prevention and treatment of ischemic heart diseases has received a wide acceptance in these recent years (1–4). In spite of their potential effectiveness to prevent Ca overload in reversibly injured myocardial cells (5,6), there is as yet little evidence that these slow channel blockers foster any therapeutic interest for the treatment of primary cardiomyopathies. The hamster hereditary cardiomyopathy includes several of the pathologic components which characterize spontaneously-occurring heart cell degeneration (7,8). The myocardial changes that progressively develop in these animals are an expression of a more generalized myopathic process which in all probability derives from an identical genetic molecular defect(s). Some ten years ago, we demonstrated that verapamil, one of the earliest Ca slow channel blockers, prevented the hamster hereditary cardiomyopathy without changing the overall course of the generalized polymyopathy that prevails in these animals (7,9). Until now, the effectiveness of verapamil in hindering the progression of skeletal muscle changes has remained unexplained except for the fact that presumably Ca slow channel blockers have no direct physiologic or pharmacologic effect on skeletal muscle fibers in higher vertebrates (10,11). Indeed therapeutic trials with prenylamine and verapamil were found unsuccessful in human muscular dystrophy (12,13).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nayler WG: The role of calcium in the ischemic myocardium. Amer J Pathol (102): 262–270, 1981.Google Scholar
  2. 2.
    Schwartz A, Grupp G, Millard RW, Grupp IL, Lathrop DA, Matlib MA, Vaghy PL, Valle JR: Calcium-channel blockers: possible mechanisms of protective effects on the ischemic myocardium. In: Weiss GB (ed) New Perspectives on Calcium Antagonists. The Williams & Wilkins Co., Baltimore, Maryland, 1981, pp. 191–210.Google Scholar
  3. 3.
    Henry PD, Clark RE, Williamson JR: Protection of the globally ischemic heart with calcium-antagonists: improved recovery after cardiopulmonary bypass. In: Fleckenstein A, Roskamm H (eds) Calcium -Antagonismus. Springer-Verlag, Berlin, Heidelberg, New York, 1980, pp. 181–190.Google Scholar
  4. 4.
    Hecht HS, Chew CYC, Burnam MH, Hopkins J, Schnugg S. Singh BN: Verapamil in chronic stable angina: amelioration of pacing-induced abnormalities of left ventricular ejection fraction, regional wall motion, lactate metabolism and hemodynamics. Amer J Cardiol (48): 536–544, 1981.PubMedCrossRefGoogle Scholar
  5. 5.
    Sperelakis N, Schneider JA: A metabolic control mechanism for calcium ion influx that may protect the ventricular myocardial cell. Amer J Cardiol (37): 1079–1085, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Fleckenstein A: Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions, in: Harris P, Opie LH (Eds) Calcium and the Heart. Academic Press, London and N.Y., 1971, pp. 135–188.Google Scholar
  7. 7.
    Jasmin G, Bajusz E: Polymyopathie et cardiomyopathie héréditaire chez le hamster de Syrie. Inhibition sélective des lésions du myocarde. Ann Anat Pathol (18): 49–66, 1973.Google Scholar
  8. 8.
    Jasmin G, Proschek L: Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM-X7.1 line. Muscle Nerve (5): 20–25, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Jasmin G, Solymoss B: Prevention of hereditary cardiomyopathy in the hamster by Verapamil and other agents. Proc Soc Exp Biol Med (149): 193–198, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Nayler WG: Calcium antagonists. In: Shibata S, Bailey LE (eds) Recent Developments in Cardiac Muscle Pharmacology. Chapter 7. Igaku-Shoin, Tokyo, 1982, pp. 99–124.Google Scholar
  11. 11.
    Stull JT, Sanford CF: Differences in skeletal, cardiac and smooth muscle contractile element regulation by calcium. In: Weiss GB (ed) New Perspectives on Calcium Antagonists. The Williams & Wilkins Co., Baltimore, Maryland, 1981, pp. 35–46.Google Scholar
  12. 12.
    Vanasse M, Jasmin G, Marois P, Lapierre-Barabe L, Proulx A, Geoffroy G, Le Lorier J: A therapeutic trial with Prenylamine, a calcium antagonist, in Duchenne muscular dystrophy. Vth Intern. Congress of Muscular Diseases, Marseille, France, 1982.Google Scholar
  13. 13.
    Emery AEH, Skinner R, Howden LC, Matthews MB: Verapamil in Duchenne muscular dystrophy. The Lancet (1): 559, 1982.CrossRefGoogle Scholar
  14. 14.
    Jasmin G, Proschek L: The paradoxical effect of Isoproterenol on hamster hereditary polymyopathy. Muscle Nerve (6): 408–415, 1983.PubMedCrossRefGoogle Scholar
  15. 15.
    Proschek L, Jasmin G: Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. II. Development of heart necrotic changes in relation to defective mitochondrial function. Muscle Nerve (5): 26–32, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Jacobson BE, Blanchaer MC, Wrogemann K: Defective respiration and oxidative phosphorylation in muscle mitochondria of hamsters in the late stages of hereditary muscular dystrophy. Can J Biochem (48): 1037–1042, 1970.PubMedCrossRefGoogle Scholar
  17. 17.
    Chance B, Williams GR: The respiratory chain and oxidative phosphorylation. Adv Enzymol (17): 65–134, 1956.Google Scholar
  18. 18.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem (193): 265–275, 1951.PubMedGoogle Scholar
  19. 19.
    Triggle DJ: Calcium antagonists: basic chemical and pharmacological aspects. In: Weiss GB (ed) New Perspectives on Calcium Antagonists. The Williams & Wilkins Co., Baltimore, Maryland, 1981, pp. 1–18.Google Scholar
  20. 20.
    Jasmin G, Proschek L: Calcium and myocardial cell injury. Can J Physiol Pharmacol (in press).Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • G. Jasmin
  • L. Proschek

There are no affiliations available

Personalised recommendations